Clinical Trials List
2025-07-01 - 2028-12-31
Phase III
Recruiting6
ICD-10E26.01
Conn's syndrome
ICD-10E26.02
Glucocorticoid-remediable aldosteronism
ICD-10E26.09
Other primary hyperaldosteronism
ICD-10E26.1
Secondary hyperaldosteronism
ICD-10E26.81
Bartter's syndrome
ICD-10E26.89
Other hyperaldosteronism
ICD-10E26.9
Hyperaldosteronism, unspecified
ICD-9255.1
Hyperaldosteronism
-
Trial Applicant
-
Sponsor
-
Trial scale
Multi-Regional Multi-Center
-
Update
2026/04/01
Investigators and Locations
Co-Principal Investigator
- 呂菁 Division of Endocrinology
The Actual Total Number of Participants Enrolled
0 Recruiting
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 陳怡婷 Division of General Internal Medicine
- CHUN-FU LAI Division of General Internal Medicine
- 黃道民 Division of General Internal Medicine
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 陳怡文 Division of Endocrinology
- 林怡瑄 Division of Endocrinology
- Kun-Hua Tu Division of Nephrology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 溫振宇 Division of Endocrinology
The Actual Total Number of Participants Enrolled
0 Recruiting
Co-Principal Investigator
- 洪啟智 Division of Nephrology
- 郭美娟 Division of Nephrology
- Yi wen chiu Division of Nephrology
- Yi-Chun Tsai Division of Nephrology
The Actual Total Number of Participants Enrolled
0 Recruiting
Condition/Disease
Objectives
Test Drug
Active Ingredient
Dosage Form
Dosage
Endpoints
Inclution Criteria
The Estimated Number of Participants
-
Taiwan
30 participants
-
Global
180 participants
